Skip to main content
TipRanks
Go Ultimate75% OFF

10x Genomics (TXG) Q3 2026 Earnings Report

1,310 Followers

TXG Q3 2026 EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.12
One Year Ago EPS
-$0.22

TXG Q3 2026 Revenue Results

Actual Revenue
$150.67M
Expected Revenue
$147.96M
Beat/Miss
Beat by +$2.70M
YoY Revenue Growth
+1.12%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
TXG Upcoming Earnings

10x Genomics's next earnings date is estimated for February 17, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

TXG Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-1.71%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. Management reported raised revenue guidance, strong consumables performance, growing Atera demand, broad customer interest, expanding AI-related opportunities, improving cash generation and progress across product and clinical initiatives. The main negatives were modest 1% total revenue growth, substantial instrument revenue declines, near-term gross margin compression from the Atera ramp, Apex-related top-line pressure and production and installation constraints.

Company Guidance

Management raised its 2026 revenue outlook to the range of $625 million to $635 million, up from $610 million to $630 million, representing 4% to 6% growth over the full year 2025 excluding nonrecurring revenue related to patent litigation settlements in both 2026 and 2025; it now expects to ship approximately 50 Atera instruments by year-end, up from the previous expectation of approximately 40, and said 50 a quarter between those constraints is about the right number going into next year. Gross margins are expected to be in the low to mid-60s for Q4, while 2027 margins will most likely come in lower than where they are because it will be an instrument heavy year and consumables will start to ramp during the course of the year; Spatial consumables in Q4 are expected to still be double digits for sure, with a full quarter of Atera consumables shipments.

  • Atera Commercial Launch and Strong Customer Demand10x Genomics began commercial shipments of Atera in September. Management said customer enthusiasm, order flow and demand momentum have continued to build, with demand not viewed as the bottleneck.
  • Atera Shipment Outlook RaisedThe company now expects to ship approximately 50 Atera instruments by year-end, up from its previous expectation of approximately 40, reflecting a production ramp that management said is progressing well.
  • Broad Atera Customer AdoptionAtera demand spans universities, academic medical centers, biopharma, biotech and service providers. Nearly all of the world's top 20 biopharma companies have purchased Atera systems or services through Catalyst.
  • Catalyst Research Services TractionIn its first five months, Catalyst Research Services had more than 100 customers book projects across a wide variety of applications and use cases.
  • Strong Interest in Whole Transcriptome WorkflowsManagement said whole transcriptome is the dominant early Atera use case and that interest has exceeded expectations, driven by customers seeking comprehensive data for AI model development.
  • Atera Platform RoadmapAtera is designed as a long-duration, upgradable platform. The roadmap includes onboard slide-preparation automation, RNA-protein multiomics and base-by-base sequencing for in-situ mutation detection.
  • Single Cell Reaction Growth and Flex Apex AdoptionSingle Cell consumables revenue grew 1%, supported by double-digit growth in reaction volumes and strong demand for Flex Apex. Management said Apex is headed toward becoming the majority of reactions in the Chromium portfolio, with adoption particularly strong in biopharma.
  • Whole Blood Workflow ExpansionNew whole blood workflows are expanding single-cell applications, including access to archival blood samples and prospective clinical collections. Management said the workflows stabilize samples, simplify processing and reduce sample variability.
  • Expansion of Multimodal and Perturbation SolutionsThe company introduced the Flex Apex CRISPR workflow, Proteintech Genomics panels and the GEM-X Multiome configuration. Management also reported increasing demand for multimodal solutions and customer investment in automation to scale experiments.
  • Sentira Cloud Analysis Platform Launch10x announced Sentira, a cloud analysis platform combining cloud computing with agentic AI analysis. Sentira Spatial uses NVIDIA-accelerated computing to reduce processing of Atera and Xenium data from hours to minutes, while Sentira Single Cell brings natural-language agentic analysis to Chromium data powered by Anthropic's Claude.
  • AI-Driven Demand TailwindManagement said most significant biological data-generation efforts are conceived at least partly to train AI models, with researchers commonly seeking multiomics, single-cell and spatial data. The company cited growing AI-focused investments in biopharma, techbio, diagnostics and sovereign healthcare AI programs.
  • Large-Scale Biological Data InitiativesPublicly announced projects involving the Cancer Research Institute, ARC Institute and CZI Biohub are progressing and scaling up. Biohub has outlined ambitions to profile hundreds of billions of cells to build predictive AI models of life.
  • Clinical Strategy ProgressThe company announced a collaboration with Fred Hutch and said it is pursuing evidence for the clinical utility of its single-cell and spatial technologies in oncology and autoimmunity. It is also making progress standing up an internal CLIA lab, with a goal of launching it next year.
  • Revenue and Consumables GrowthThird-quarter revenue was $150.7 million, up 1% year-over-year. Total consumables revenue increased 5%, with growth in both Single Cell and Spatial.
  • Spatial Consumables MomentumSpatial consumables revenue grew 16%, driven primarily by Xenium consumables. Management said third-quarter performance was modestly better than anticipated, Xenium pull-through remained strong, and Spatial consumables are expected to grow at double-digit rates in the fourth quarter.
  • Improved Gross MarginGross margin increased to 75% from 67% in the prior-year period, primarily due to lower inventory write-downs and changes in product mix.
  • Lower Operating ExpensesTotal operating expenses decreased to $129 million from $132.5 million in the prior-year period, primarily due to lower personnel and lab equipment expenses, partially offset by higher litigation expenses.
  • Strengthened Cash PositionThe company ended the quarter with $576 million in cash, cash equivalents and marketable securities, up $94 million year-over-year and $24 million sequentially.
  • Raised Full-Year Revenue OutlookManagement raised 2026 revenue guidance to $625 million-$635 million from $610 million-$630 million. Excluding nonrecurring patent litigation settlement revenue in both 2026 and 2025, the outlook represents 4%-6% growth over full-year 2025.
  • Positive Early Atera Customer FeedbackAlthough the launch is still very early, management said initial installations and customer runs have been going well. The company reported that platform specifications and data quality have continued to improve, with customer feedback described as phenomenal.
  • Higher Long-Term Atera Gross Margin ProfileManagement said the overall gross margin profile of the Atera platform is superior to Xenium, with both Atera instruments and consumables expected to have notably higher margins.

TXG Earnings History

TXG earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 17, 20272026 (Q4)-0.22--0.13――
Nov 05, 20262026 (Q3)-0.27-0.15-0.2231.82% (+0.07)
Aug 06, 20262026 (Q2)-0.24-0.140.28-150.00% (-0.42)
May 07, 20262026 (Q1)-0.28-0.10-0.2864.29% (+0.18)
Feb 12, 20262025 (Q4)-0.20-0.13-0.467.50% (+0.27)
Nov 06, 20252025 (Q3)-0.29-0.22-0.326.67% (+0.08)
Aug 07, 20252025 (Q2)-0.370.28-0.32187.50% (+0.60)
May 08, 20252025 (Q1)-0.47-0.28-0.544.00% (+0.22)
Feb 12, 20252024 (Q4)-0.30-0.40-0.412.44% (+0.01)
Oct 29, 20242024 (Q3)-0.33-0.30-0.7962.03% (+0.49)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed